Navigation Links
Experimental agents may prevent radiation-induced leukemia

DENVER Treatment with biphosphonates could prevent radiation-induced leukemia, according to data presented at the American Association for Cancer Research 100th Annual Meeting 2009.

Alexandra Miller, Ph.D., a senior scientist at the Armed Forces Radiobiology Research Institute, said her research is designed to help military and space agency personnel, who are more likely to be exposed to risky levels of radiation than the general population. However, she said the research could have applications for civilian populations as well.

"It is possible, although not yet proven, that the compound we studied could have a general effect on leukemia associated with causes other than radiation, such as age, which is much more common," said Miller.

The compounds Miller studied are biphosphonates known to scientists as ethane-1-hydroxy-1, 1-biphosphonate (EHBP) and carballylic amido bis phosphonic acid (CAPBP). Biphosphonates have emerged as an attractive chemopreventive agent due to earlier research that suggests they prevent bone metastasis and because they have an ability to remove uranium from the body.

For the current study, Miller and her colleagues irradiated laboratory mice at 3.5 Gy; all of the mice who were not treated with either EHBP or CAPBP developed leukemia.

By contrast, if they were treated with six doses of EHBP only 75 percent of mice developed leukemia. Similarly, only 65 percent of mice treated with CAPBP developed leukemia.


Contact: Jeremy Moore
American Association for Cancer Research

Page: 1

Related medicine news :

1. Experimental insulin-like growth factor receptor inhibitor reduced pancreatic cancer growth
2. Hard to Treat Diseases (HTDS) Releases experimental results in the treatment of (MS) Multiple Sclerosis
3. Experimental Drug May Dampen Severe Asthma
4. Experimental Drug May Prevent Plaque Buildup
5. Experimental Biology 2009 meets April 18-22
6. Experimental Weight-Loss Pill Passes Early Test
7. Experimental Drug Fights Bone Marrow Cancers
8. Experimental Vaginal Gel Doesnt Ward Off HIV
9. Experimental TB drug explodes bacteria from the inside out
10. Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
11. Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data
Post Your Comments:
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids this ... by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited about ... ages; it is a non-competitive, non-timed event, which is all about having fun and ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... 2017  Commended for their devotion to personalized service, SMP ... number one in the South Florida Business Journal,s 50 Fastest-Growing ... yearly list, the national specialty pharmacy has found its niche.  ... will soon be honored by SFBJ as the 2017 Power ... Set to receive his award in October, Bardisa said of ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
Breaking Medicine Technology: